Research programme: autoimmune and inflammatory disease antibody therapeutics - Ogeda/Medarex

Drug Profile

Research programme: autoimmune and inflammatory disease antibody therapeutics - Ogeda/Medarex

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator Euroscreen; Medarex
  • Developer Medarex; Ogeda
  • Class Antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation

Most Recent Events

  • 19 Oct 2016 Euroscreen is now called Ogeda
  • 29 Sep 2009 Preclinical development is ongoing in USA
  • 28 Jun 2006 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top